<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-03T15:52:43Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/062E380C-4D75-4AFB-B89B-3DA7C48D32BF" ns1:id="062E380C-4D75-4AFB-B89B-3DA7C48D32BF"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/991F4538-1C13-479A-95E3-2A14A871F85E" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/BE0303A2-1F4F-4B0F-A23F-7644931F6A37" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/432C41E3-AE5D-47CF-8B52-D41896F71FA6" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/13237A32-821F-43EB-8768-EC049DBF184F" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/BE0303A2-1F4F-4B0F-A23F-7644931F6A37" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/DBFBA28D-BA56-4C34-96F3-3CBD054DBA45" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2025-03-30T23:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/4322A8B7-1BA8-4AA2-98D5-A62F349C09D8" ns1:rel="FUND" ns1:start="2022-09-30T23:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">10029053</ns2:identifier></ns2:identifiers><ns2:title>Maximising bioproduction in CHO cell by interdisciplinary engineering and AI</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Collaborative R&amp;D</ns2:grantCategory><ns2:leadFunder>ISCF</ns2:leadFunder><ns2:abstractText>Although CHO cells are one of the most highly employed cell lines in bioproduction (with \&amp;gt;&amp;pound;100 Billion market), current commercially available CHO cells inability to adapt and restore cell balance leads to stress-induced apoptosis and undesirable protein modifications. Further, the biotechnology industry lacks in-line methods to examine the actual cell viability during production in small or large-scale experiments. These pain points limit CHO-based recombinant protein production's efficiency and yield, leading to a considerable waste of resources, time and materials in manufacturing.

GeneNet Technology, in collaboration with CPI (Centre for Process Innovation) and Taiwan based Cytena BPS and Instant NanoBiosensor, is here to engineer a stress sensing genetic circuit and AI cell embedded to current bioproduction (incubator) in real-time testing method. Combining cutting edge technology from Cytena BPS' next-generation bioreactor, which allows culture fine-tuning and real-time data collection from culturing and physiological conditions, and Instant NanoBiosensors' Fiber Optic Particle Plasmon Resonance technology which detects biomarker expression, we will gather comprehensive culturing, physiological and biomarker data during CHO cell bioproduction. This comprehensive data will be fed into GeneNet's ground-breaking technology, Artificial neural network (ANN) genetic circuits. ANN genetic circuits are the cutting-edge technology in synthetic biology and genetic engineering. In the past decade, synthetic genetic circuits only apply simple logic (AND/OR/NOT) gates to biocomputing. GeneNet's ground-breaking technology makes genetic circuits analogous to deep learning computers, turning CHO cells into smarter AI computers. All this will enable us to engineer smart, stress-sensing CHO cells to maximise protein production efficiency and yield, benefiting our downstream clients and wider industry and society as a whole.</ns2:abstractText></ns2:project>